Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Impax Laboratories Recalls Lamotrigine Due to Improper Blister Pack Labeling

By Meg Snyder | August 30, 2016

On August 19, Impax Laboratories, Inc. issued a voluntary nationwide recall for one lot of Lamotrigine Orally Disintegrating Tablet (ODT) 200 mg, a treatment that is indicated for the treatment of epilepsy and bipolar disorders.

NDC Number Blister Pack Lot Number
0115-1529-08 30 502240

According to the press release, the affected lot was distributed “between June 13, 2016 and August 10, 2016 to wholesale distributors and retail pharmacies nationwide.” 

About the affected product:

  • One unit-of-use blister packs is a 10 count blister card contained in a single plastic shell-pack (200 mg)
  • These unit-of-use blister packs may contain 100 mg product (instead of 200 mg product)
  • Each blister card is properly labeled (as 100 mg ODT) 
  • The plastic shell pack containing the 100 mg blister cards is labeled as 200 mg ODT

According to the FDA, “[s]hell-packs from the affected lot may contain 100 mg ODT instead of 200 mg ODT, and as a result, it is possible that consumers could take less than their intended lamotrigine dose. A reduction in dose may lead to reduced therapeutic effects of lamotrigine and reemergence of epilepsy or bipolar disorder symptoms.”

The FDA is asking consumers to “carefully inspect their medication.”

For more information about this recall, click here. 

Photo courtesy of the FDA.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!  

Related Articles Read More >

kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Disposable syringe and American currency on black background
PBMs increasingly under fire in drug-pricing battle
Johnson & Johnson logo
Timeline: Navigating Johnson & Johnson’s talc lawsuits and their stock performance impact
pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory
5 core trends in drug recalls: An analysis of 2022 and Q1 2023
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE